期刊
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
卷 45, 期 -, 页码 1-8出版社
WILEY
DOI: 10.1111/eci.12363
关键词
Cancer; immunity; pDC; plasmacytoid dendritic cells; tolerance; tumour
资金
- National Institutes of Health [AI078234]
- Department of Defense [GW100091]
- Program of Competitive Growth of Kazan Federal University
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI078234] Funding Source: NIH RePORTER
BackgroundPlasmacytoid dendritic cells (pDCs) are multifunctional bone-marrow-derived immune cells that are key players in bridging the innate and adaptive immune systems. Activation of pDCs through toll-like receptor agonists has proven to be an effective treatment for some neoplastic disorders. Materials and methodsIn this mini-review, we will explore the fascinating contribution of pDCs to neoplastic pathology and discuss their potential utilization in cancer immunotherapy. ResultsCurrent research suggests that pDCs have cytotoxic potential and can effectively induce apoptosis of tumour-derived cells lines. They are also reported to display tolerogenic function with the ability to suppress T-cell proliferation, analogous to regulatory T cells. In this capacity, they are critical in the suppression of autoimmunity but can be exploited by tumour cells to circumvent the expansion of tumour-specific T cells, thereby allowing tumours to persist. ConclusionSeveral forms of skin cancer are successfully treated with the topical drug Imiquimod, which activates pDCs through toll-like receptor 7 engagement. Additionally, pDC-based anticancer vaccines have shown encouraging results for the treatment of melanoma in early trials. Future studies regarding the contributions of pDCs to malignancy will likely afford many opportunities for immunotherapy strategies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据